Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?

Digestive and Liver Disease

Volumn 39, Issue 2, 2007, Pages 156-159

  Gilissen, L P L ^a   Derijks, L J J ^b   Driessen, A ^a   Bos, L P ^c   Hooymans, P M ^c   Stockbrugger R W ^a   Engels, L G J B ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

Author keywords

6 Thioguanine; Hepatotoxicity; Inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; TIOGUANINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG MONITORING; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; HYPERPLASIA; LIVER BIOPSY; LIVER HISTOLOGY; LIVER NODULE; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; TREATMENT DURATION;

ADULT; BIOPSY; COHORT STUDIES; FEMALE; HUMANS; HYPERPLASIA; INFLAMMATORY BOWEL DISEASES; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; THIOGUANINE;

EID: 33846266585     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.10.007     Document Type: Article

References (23)

1. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., and Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. 111 (1989) 641-649
2. Adler D.J., and Korelitz B.I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am. J. Gastroenterol. 85 (1990) 717-722
3. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
4. Dubinsky M.C., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. 7 (2001) 181-189
5. Al Hadithy A.F., de Boer N.K., Derijks L.J., Escher J.C., Mulder C.J., and Brouwers J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig. Liver Dis. 37 (2005) 282-297
6. Baert F., and Rutgeerts P. 6-Thioguanine: a naked bullet? (or how pharmacogenomics can make old drugs brand new). Inflamm. Bowel Dis. 7 (2001) 190-191
7. Derijks L.J., De Jong D.J., Gilissen L.P., Engels L.G., Hooymans P.M., Jansen J.B., et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15 (2003) 63-67
8. Dubinsky M.C., Feldman E.J., Abreu M.T., Targan S.R., and Vasiliauskas E.A. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am. J. Gastroenterol. 98 (2003) 1058-1063
9. Bonaz B., Boitard J., Marteau P., Lemann M., Coffin B., Flourie B., et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol. Ther. 18 (2003) 401-408
10. Herrlinger K.R., Deibert P., Schwab M., Kreisel W., Fischer C., Fellermann K., et al. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol. Ther. 17 (2003) 1459-1464
11. Herrlinger K.R., Kreisel W., Schwab M., Schoelmerich J., Fleig W.E., Ruhl A., et al. 6-Thioguanine-efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol. Ther. 17 (2003) 503-508
12. de Boer N.K.H., Derijks L.J.J., Gilissen L.P.L., Hommes D.W., Engels L.G.J.B., de Boer S.Y., et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J. Gastroenterol. 11 (2005) 5540-5544
13. Dubinsky M.C., Vasiliauskas E.A., Singh H., Abreu M.T., Papadakis K.A., Tran T., et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
14. Seiderer J., Zech C.J., Reinisch W., Lukas M., Diebold J., Wrba F., et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J. Hepatol. 43 (2005) 303-309
15. Stromeyer F.W., and Ishak K.G. Nodular transformation (nodular regenerative hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum. Pathol. 12 (1981) 60-71
16. Naber A.H.J., Van Haelst U., and Yap S.H. Nodular regenerative hyperplasia of the liver: in important cause of portal hypertension in non-cirrhotic patients. J. Hepatol. 12 (1991) 94-99
17. Zarday Z., and Veith F.J. Irreversible liver damage after azathioprine. J. Am. Med. Assoc. 222 (1972) 690-691
18. Russmann S., Zimmermann A., Krähenbühl S., Kern B., and Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 13 (2001) 287-290
19. Daniel F., Cadranel J.F., Seksik P., Cazier A., Duong Van Huyen J.P., Ziol M., et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol. Clin. Biol. 29 (2005) 600-603
20. Tremaine W.J. Editorial: 6-TG for IBD: simple, but safe?. Am. J. Gastroenterol. 98 (2003) 950-952
21. Wanless I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11 (1990) 787-797
22. Katzka D.A., Saul S.H., Jorkasky D., Sigal H., Reynolds J.C., and Soloway R.D. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 90 (1986) 446-454
23. de Boer N.K., Reinisch W., Teml A., van Bodegraven A.A., Schwab M., Lukas M., et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 73 (2006) 25-31